Cardiac hypertrophy induced by PPAR-γ agonist treatment occurs independently of changes in myocardial insulin signaling

被引：0
|
作者：
Rasmussen, I
McQueen, AP
Zaha, VG
Litwin, SE
Berger, JP
Abel, ED
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] Merck & Co Inc, Rahway, NJ 07065 USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1541
引用
收藏
页码：321 / 322
页数：2
相关论文
共 50 条
  • [21] The PPAR-γ-activating ARB irbesartan stimulates expression of the insulin-signaling protein CAP and enhances insulin-induced glucose uptake
    Clemenz, M
    Frank, J
    Schupp, M
    Goebel, M
    Unger, T
    Kintscher, U
    CIRCULATION, 2004, 110 (17) : 834 - 834
  • [22] Prevention of transient middle cerebral artery occlusion-induced inflammation and infarction by PPAR-γ agonist treatment in SHR ra
    Sundaresan, R
    Satriotomo, I
    Bowen, K
    Vemuganti, R
    JOURNAL OF NEUROCHEMISTRY, 2005, 94 : 95 - 95
  • [23] SIRT3 inhibits Ang II-induced transdifferentiation of cardiac fibroblasts through β-catenin/PPAR-γ signaling
    Guo, Xiaobin
    Yan, Fangying
    Shan, Xiaolan
    Li, Jingyuan
    Yang, Yi
    Zhang, Jie
    Yan, Xuefang
    Bu, Peili
    LIFE SCIENCES, 2017, 186 : 111 - 117
  • [24] TRPV1 Activation Attenuates High-Salt Diet-Induced Cardiac Hypertrophy and Fibrosis through PPAR-δ Upregulation
    Gao, Feng
    Liang, Yi
    Wang, Xiang
    Lu, Zongshi
    Li, Li
    Zhu, Shanjun
    Liu, Daoyan
    Yan, Zhencheng
    Zhu, Zhiming
    PPAR RESEARCH, 2014, 2014
  • [25] PPAR-α and -γ agonist for the treatment of animal model of non-alcoholic fatty liver disease is effective in improving histological and biochemical changes
    Yeon, J
    Choi, K
    Baik, S
    Chang, Y
    Lee, J
    Seo, Y
    Kim, J
    Park, J
    Kim, J
    Byun, K
    Bakl, Y
    Lee, C
    JOURNAL OF HEPATOLOGY, 2005, 42 : 257 - 257
  • [26] Treatment with the insulin-sensitizing PPAR-? agonist rosiglitazone preserves cognition and modulates plasma a-amyloid in patients with AD and amnestic MCI
    Craft, S
    Watson, GS
    Baker, L
    Cholerton, B
    Reger, M
    Plymate, S
    Fishel, M
    Kahn, S
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 104 - 104
  • [27] A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy
    Zeng, Si-Yu
    Lu, Hui-Qin
    Yan, Qiu-Jiang
    Zou, Jian
    PPAR RESEARCH, 2018, 2018
  • [28] Insulin receptor signaling in cardiomyocytes protects against myocardial injury during cardiac hypertrophy by regulating capillary density
    McQueen, A
    Zhang, DF
    Hu, P
    Zaha, V
    Hoffman, J
    Yun, UJ
    Wang, ZM
    Albertine, K
    Abel, ED
    Litwin, SE
    CIRCULATION, 2005, 112 (17) : U332 - U332
  • [29] Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist
    Sun, Ji-Min
    Wang, Chun-Miao
    Guo, Zeng
    Hao, Yu-Yu
    Xie, Yang-Jing
    Gu, Jian
    Wang, Ai-Ling
    MOLECULAR MEDICINE REPORTS, 2015, 11 (03) : 1845 - 1850
  • [30] Long-term constitutive activation of insulin signaling induced maladaptive cardiac hypertrophy, but did not accelerate cardiac aging
    Inuzuka, Yasutaka
    Kato, Takao
    Tamaki, Yodo
    Kawashima, Tsuneaki
    Niizuma, Shinichiro
    Kita, Toru
    Shioi, Tetsuo
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 45 : S19 - S19
12345